Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.39 USD | -0.94% | +3.54% | +22.81% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.81% | 577.7Cr | |
+8.29% | 11TCr | |
+10.21% | 10TCr | |
+0.41% | 2.23TCr | |
-11.90% | 2.24TCr | |
-5.99% | 1.91TCr | |
-37.36% | 1.8TCr | |
-5.17% | 1.79TCr | |
+7.70% | 1.43TCr | |
+37.65% | 1.25TCr |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Wells Fargo Adjusts Halozyme Therapeutics' Price Target to $55 From $65, Keeps Overweight Rating